Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $200

Benzinga Newsdesk www.benzinga.com Positive 82.5%

Neg 0% Neu 0% Pos 82.5%

Guggenheim analyst Brad Canino maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $175 to $200.